The EV-302 study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS), compared to chemotherapy. An Independent Data Monitoring Committee determined that OS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback